Intellia Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 13.23 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.85B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;...